Prolight secures two additional European patents for Psyros®

Prolight Diagnostics announces today that the European Patent Office (EPO) has issued “Intention to Grant” notifications for two separate patent applications relating to the Psyros single-molecule-counting technology.The official notification date for both patents is 28 October, 2026.   “We are delighted to have received Intention to Grant notifications for two additional patents in Europe on the […]

Prolight receives first order of approximately SEK 19.9 million from BRAINBox

Prolight Diagnostics AB (publ) today announces that the company has received its first purchase order from BRAINBox Solutions under the supply agreement announced in September 2026. The order value amounts to approximately SEK 19.9 million and covers commercial products ahead of BRAINBox’s planned US launch in traumatic brain injury (TBI). The order covers commercial products for […]

BioStock publishes article after Prolight signed supply agreement with BRAINBox valued at USD 3.9 million

BioStock publishes article after Prolight Diagnostics signed supply agreement with BRAINBox valued at USD 3.9 million during the first year, with comments from Prolight. Read the full article here: https://biostock.se/en/2026/09/prolight-comments-on-usd-3-9m-brainbox-deal/  For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics develops Psyros®, a groundbreaking Point-of-Care platform for highly sensitive […]

Prolight signs supply agreement with BRAINBox valued at USD 3.9 million for the first year

Prolight Diagnostics AB (publ), pioneer in digital point of care testing, today announced that it has signed a supply agreement with BRAINBox Solutions for instruments and cartridges. Anticipated first year supply post FDA clearance and market launch is valued at USD 3.9 million (approximately SEK 37 million). The agreement supports the commercialisation of BRAINBox’s traumatic […]

Prolight Diagnostics publishes half-year report, 2026

Financial overview Second quarter, April 1 – June 30, Q2 2026(Figures in parentheses refer to the corresponding period in the previous year.)· Net sales amounted to 0 (0).· Other operating income amounted to 2,840 (13,945) thousand SEK.· Operating profit (EBIT) amounted to -8,304 (-15,346) thousand SEK.· Profit after tax amounted to -8,304 (-12,740) thousand SEK.· Earnings per share before and […]

Prolight signs GBP 2.24m development agreement with BRAINBox

Prolight Diagnostics today announces the successful completion of a 260-patient feasibility study and the subsequent signing of a development agreement with BRAINBox Solutions. The agreement generates revenues of approximately GBP 2.24 million (SEK 29 million) of which GBP 2,09 million (SEK 27 million) is to be recognized during the second half of 2026. In the feasibility […]

Prolight receives Notice of Allowance for Psyros® patent in the US

Prolight Diagnostics today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance relating to a patent application covering key aspects of the Psyros® single-molecule-counting technology. This is expected to become the first granted U.S. patent relating to the Psyros platform. The patent application (US application No. 18/267,726) covers methods to extend […]

Prolight Diagnostics publishes quarterly report Q1, 2026

First quarter, January 1 – March 31, 2026 Net sales amounted to 0 (0). Other operating income amounted to 1,201 (1,662) thousand SEK. Operating profit (EBIT) amounted to -10,389 (10,937) thousand SEK. Profit after tax amounted to -10,389 (-10,937) thousand SEK. Earnings per share before and after dilution: -0.86 (-1.55) SEK. Cash flow from operating activities was -12,640 (-9,176) thousand SEK.  […]

Annual general meeting of Prolight Diagnostics AB (publ) on 26 May 2026

The annual general meeting (AGM) of Prolight Diagnostics AB (publ) took place on 26 May 2026 in Stockholm. Full information regarding the decisions of the AGM is available on the company’s website, www.prolightdx.com. The AGM resolved in accordance with all of the motions presented in the notification of the AGM except for the election of […]

Prolight Diagnostics AB (publ) publishes annual report for 2025

Prolight Diagnostics AB (publ) has today published its Annual Report for the financial year 2025. The report is available via the attached file or on the Company’s website: https://prolightdx.com/en/investors/financial-reports/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care systems. These are small, […]